Catherine Diefenbach, MD
Enriched profileProfessor, Department of Medicine, NYU Grossman School of Medicine; Director, Hematology Translational Research and Director, Clinical Lymphoma Program, Perlmutter Cancer Center · NYU Langone Health
Catherine Diefenbach is Professor, Department of Medicine, NYU Grossman School of Medicine; Director, Hematology Translational Research and Director, Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health. OpenAlex indexes 380 publications with 5,600 citations (h-index 35); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Catherine Diefenbach, M.D., is Professor, Department of Medicine, NYU Grossman School of Medicine at NYU Langone Health / NYU Grossman School of Medicine (Perlmutter Cancer Center). The public record shows 380 publications with 5,600 citations (h-index 35), centered on Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 16 companies, 4 NIH-funded awards (2014–2026).
- Most recent indexed publication: 2026 · Blood advances
- Top research focus: Lymphoma Diagnosis and Treatment
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 16 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 99.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Sponsor: National Cancer Institute (NCI)
- Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Sponsor: Academic and Community Cancer Research United
- Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- BeOne Medicines USA, Inc.Program year20254 payments
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Corticosteroid100%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
4 NIH research awards on record, funded 2014–2026 per NIH RePORTER. The latest:
- LTBR CARs as next-generation therapies for R/R lymphoma
New York Genome Center
FY2026$819,260R01CA279135 - A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
New York University School of Medicine
FY2026$700,559R01CA269617 - LTBR CARs as next-generation therapies for R/R lymphoma
New York Genome Center
FY2025$810,022R01CA279135
Congress activity
Updated 27 Aug 2026
91 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Brentuximab vedotin and nivolumab for untreated patients with Hodgkin lymphoma: long-term results.
Blood advances
Article2025 - A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.
Blood advances
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01The bone marrow microenvironment at single-cell resolutionArticle945 citations2019
- 02
- 03
- 04
- 05A genome-scale screen for synthetic drivers of T cell proliferationArticle187 citations2022
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/catherine-diefenbach-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/issues/february-10-2023/epov-catherine-s-diefenbach-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Other
lls.org/award-recipient/catherine-diefenbach
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lls.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Editorial & leadership roles
journal and society appointments- Committee Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗ - Lymphoma Committee Member
ECOG-ACRIN Cancer Research Group
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Awards & honors
honors on the public record- Award Recipient
Leukemia & Lymphoma Society / Blood Cancer United (Career Development Program area of research funding)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lls.org ↗
Media & interviews
press, podcasts and appearances- Video interview series on lymphoma topics
VJHemOnc (speaker profile with multiple interviews)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗ - Contributor/interviewee
OncLive (author page featuring lymphoma coverage and interviews)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Harvey Pass, MD
NYU Langone Health
Gareth Morgan, MD
NYU Langone Health
Douglas Kondziolka, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health